

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/485,193
Filing Date	June 3, 1999
First Named Inventor	Schneider, Patrick A.
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	018002-001010US



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SZ	AA	BRUNER et al. "Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice," J. Clin. Invest 99:2851-2857 (1997).	
	AB	GIUDICE et al. "Status of current research on endometriosis," J Reprod Med 43:252-262 (1998).	
X	AC	SBURLATI et al. "prothymosin alpha antisense oligomers inhibit myeloma cell division," Proc. Acad. Sci. USA 88:253-257 (1991).	

INCOMPLETE - 3 of 5 pages only

Examiner Signature

S. Z. Y. Jones

Date Considered

1-26-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3192711 v1

APP 5

01/05/99

FORM PTO-1449 (Modified)		Attorney Docket No.: 18002-001010US		Application No.: 09/485,193	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Patrick A. Schneider <i>et al.</i>		Filing Date: June 3, 1999	
Reference Designation		U.S. PATENT DOCUMENTS		Page 1	
Examiner Initial	Document No.	Date	Name	Class	Sub-class
AA	5,248,591	09/28/93	Puente	435	7.1
AB	4,696,915	09/29/87	Horecker	514	21
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-class
AC	WO 95/32708	12/07/95	PCT		
AD	WO 98/12324	03/26/98	PCT		
AE	WO 98/42185	01/10/98	PCT		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AF	Baxevanis, Constantin N. <i>et al.</i> , "Prothymosin α Enhances Human and Murine MHC Class II Surface Antigen Expression and Messenger RNA Accumulation," 148(7):1979-1984 (1992)				
AG	Hill, Joseph A., MD, "Immunology and Endometriosis," <i>Obstetrics and Gynecology Clinics of North America</i> 24(2):291-306 (1997)				
AH	Ota and Igarashi, "Expression of major histocompatibility complex class II antigen in endometriotic tissue in patients with endometriosis and adenomyosis," <i>Fertility and Sterility</i> 60(5):834-838 (1993)				
AI	Oikawa, Mamoru <i>et al.</i> , "Expression of Gonadotropin-Releasing Hormone and Prothymosin- α Messenger Ribonucleic Acid in the Ovary," <i>Endocrinology</i> 127(5):2350-2356 (1990)				
AJ	Ota, H. <i>et al.</i> , "Is adenomyosis an immune disease?," <i>Hum Reprod Update</i> 4(4):360-7 (1998) ABSTRACT ONLY				
AK	Sharpe-Timms, Kathy L., PhD, HCLD, "Basic Research in Endometriosis," <i>Obstetrics and Gynecology Clinics of North America</i> 24(2):269-290 (1997)				
EXAMINER		DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.